MetaStat

MetaStat Cash & Equivalents

The Cash & Short-Term Investments of MetaStat (MTST) as of Nov 22, 2026 is 316,933.00 USD. In the previous year, Cash & Short-Term Investments was 782,707.00 USD — a change of -59.51% (lower).

Cash & Equivalents

316,933.00USD

YoY

-59.51%

Last updated:

Cash & Short-Term Investments of MetaStat is 2018 316,933.00 USD. Cash & Short-Term Investments of MetaStat was 2017 782,707.00 USD. It decreases by -59.51% lower compared to the previous year.

The MetaStat Cash & Equivalents history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash & Equivalents
Date
Cash & Equivalents
Jan 1, 2014
483,408.00 USD
Jan 1, 2015
257,820.00 USD
Jan 1, 2016
363,783.00 USD
Jan 1, 2017
782,707.00 USD
Jan 1, 2018
316,933.00 USD
The MetaStat Cash & Equivalents history
YEARCash & EquivalentsYoY
316,933.00USD-59.51%
782,707.00USD+115.16%
363,783.00USD+41.10%
257,820.00USD-46.67%
483,408.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

Cash & Short-Term Investments of MetaStat is 316,933.00 USD in 2018.

Cash & Short-Term Investments of MetaStat changed from 782,707.00 USD to 316,933.00 USD, representing a -59.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash & Short-Term Investments MetaStat since 2006 – with annual values, charts, and detailed analysis.

Cash and equivalents represent the most liquid assets on the balance sheet, available for immediate use or short-term obligations.

Cash & Short-Term Investments's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cash & Short-Term Investments's MetaStat historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MetaStat

All Key Metrics — MetaStat